This research investigates how HIV disrupts the developing immune system in early life. Using a baby monkey model of HIV infection, the study identifies immune signals that either promote or limit infection spread. The findings could guide new immune-targeted therapies that improve survival and long-term outcomes for children living with HIV.

This research investigates how antiviral drug resistance develops by examining structural changes in viral proteins. Using protein crystallography, it identified why SARS-CoV-2 mutations prevent Paxlovid binding and discovered two compounds capable of inhibiting resistant viruses. The findings could guide development of more effective antivirals against future drug-resistant viral infections.

This research improves combination vaccines by addressing antigen competition using injectable hydrogels that slowly release antigens. This approach produces balanced immune responses to multiple diseases, unlike traditional vaccines. The innovation could reduce the number of shots required, improve global vaccine access, and ensure more effective immunization, particularly in underserved populations.

This research develops small-molecule treatments for chikungunya virus using a lock-and-key approach targeting viral proteins. A key challenge—molecular orientation (enantiomers)—was addressed with a new synthesis method producing over 95% effective molecules. The optimized compound, BDGR-651, shows promise as a future antiviral treatment for this debilitating disease.

This research investigates COVID-19 stigma among survivors in Nepal during the pandemic. It found that one-quarter experienced discrimination, social exclusion, and psychological distress. Misinformation, weak health-system preparedness, and lack of public trust fuelled stigma. The study argues that future pandemic preparedness must address social stigma alongside healthcare capacity.